Sanofi has been in the Egyptian manufacturing game for decades, but that doesn’t mean the French pharma can’t use a helping hand from time to time.

赛诺菲在埃及制造业已经有几十年的历史，但这并不意味着这家法国制药公司不能不时伸出援手。

Take for instance the company’s new deal with local drugmaker Minapharm, which grants exclusive control over manufacturing and supply of Sanofi’s popular anticoagulant Clexane, also known as enoxaparin, in Egypt.

以该公司与当地制药商Minapharm的新政为例，该新政授予赛诺菲在埃及生产和供应广受欢迎的抗凝剂Clexane（也称为依诺肝素）的独家控制权。

The deal is set to boost Egypt’s national localization strategy of biopharmaceutical manufacturing, the companies said in a press release Sunday. Minapharm, for its part, also oversees subsidiaries in Cairo and Berlin, Germany.

两家公司在周日的新闻稿中表示，该协议将推动埃及生物制药制造的国家本地化战略。米纳法姆（Minapharm）也负责监管开罗和德国柏林的子公司。

Clexane production is set to take place in Minapharm’s second new biopharmaceutical facility in Egypt, which is designed for research, development and manufacturing of complex bioengineered proteins.

Clexane的生产将在Minapharm位于埃及的第二家新生物制药工厂进行，该工厂旨在研究、开发和制造复杂的生物工程蛋白。

Related

相关

Gates Foundation spends $40M to boost mRNA vaccine production in Africa and beyond

盖茨基金会（Gates Foundation）斥资4000万美元，用于促进非洲及其他地区的mRNA疫苗生产

Sanofi already has an upsized presence in Egypt, where the company employs some 1,200 staffers. The company has also operated a manufacturing site in Cairo since 1962 that currently produces 120 million units of medicine each year.

赛诺菲已经在埃及扩大了业务规模，该公司在埃及雇佣了约1200名员工。自1962年以来，该公司还在开罗经营一个生产基地，目前每年生产1.2亿单位药品。

Minapharm, which itself operates out of Cairo, touts its position as the “premier biopharmaceutical company in Africa.” The company commercializes over 100 drug products ranging from small molecules to complex genetically engineered proteins. Collectively, Minapharm oversees more than 2,000 employees..

Minapharm本身在开罗运营，吹嘘其“非洲首屈一指的生物制药公司”的地位。该公司将100多种药物产品商业化，从小分子到复杂的基因工程蛋白。Minapharm总共管理着2000多名员工。。

Africa has been a popular destination for pharmaceutical manufacturing ventures in recent years.

近年来，非洲一直是制药企业的热门目的地。

In April, the World Health Organization tapped South African biotech Afrigen Biologics to help steer an agency-backed mRNA vaccine hub in Cape Town. Under the arrangement, Afrigen is using the publicly available sequence of Moderna’s COVID shot Spikevax to make its own version of the prophylactic, AfriVac 2121, at lab scale..

4月，世界卫生组织利用南非生物技术公司Afrigen Biologics帮助在开普敦建立一个由机构支持的mRNA疫苗中心。根据安排，Afrigen正在使用Moderna的新型冠状病毒疫苗Spikevax的公开序列，在实验室规模上制造自己的预防药物AfriVac 2121。。

Related

相关

Strides African unit nabs WHO first with nod to produce malaria treatment

世界卫生组织非洲单位nabs率先点头生产疟疾治疗药物

In June, meanwhile, China’s Fosun Pharma unveiled plans to build a facility in the Ivory Coast to crank out antimalaria drugs and antibacterial medicines with the help of a 100 million euro ($106 million) loan from the International Finance Corporation (IFC).

与此同时，6月，中国复星制药（Fosun Pharma）宣布计划在国际金融公司（IFC）的一亿欧元（1.06亿美元）贷款的帮助下，在科特迪瓦建立一家生产抗疟药和抗菌药的工厂。